Mesenchymal Tumor – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mesenchymal Tumor – Drugs In Development, 2024 report and make more profitable business decisions.
Mesenchymal tumors are tumors developing from mesenchymal tissues. These tissues are made of cells including fibroblasts, nerve cells, blood vessel cells, muscle cells, and others. Benign soft tissue tumors are common in humans, but cancerous mesenchymal tumors are rare. Many tumors can originate from various cells, and the treatment mainly depends on the tumor’s type, severity, and aggressiveness. These are soft tissue tumors that occur due to any aberrancy during the developmental differentiation of mesenchymal tissue into fat, skeletal muscle, peripheral nerves, blood vessels, and fibrous tissues. One possible cause is mutations in genes that code for proteins controlling cell division. Having a family history of soft tissue tumors also increases the risk, but most mesenchymal tumors develop without any apparent risk factors.
The Mesenchymal Tumor drugs in development market research report provide comprehensive information on the therapeutics under development for Mesenchymal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mesenchymal Tumor and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mesenchymal Tumor | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 80 molecules, with 76 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mesenchymal Tumor therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mesenchymal Tumor pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mesenchymal Tumor treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aadi Bioscience IncAB Science SA
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
Allarity Therapeutics Inc
Alligator Bioscience AB
Alyra Therapeutics Inc
Arog Pharmaceuticals Inc
Ascentage Pharma Group International
Bayer AG
Beijing Immunochina Pharmaceuticals Co Ltd
BioAtla Inc
Blueprint Medicines Corp
Chang Gung Memorial Foundation
Chinese Academy of Sciences
Clinigen Ltd
Cogent Biosciences Inc
CStone Pharmaceuticals Co Ltd
Deciphera Pharmaceuticals Inc
DNAtrix Inc
Eisai Co Ltd
Eli Lilly and Co
Esperas Pharma Inc
F. Hoffmann-La Roche Ltd
Guangzhou Institute of Biomedicine and Health
Handok Inc
Hanmi Pharmaceuticals Co Ltd
Hefei Cosource Pharmaceutical Inc
Hoth Therapeutics Inc
IDRx Inc
Inhibrx Inc
Kinnate Biopharma Inc
Kyowa Kirin Co Ltd
Lotus Pharmaceutical Co Ltd
Mendus AB
Merck & Co Inc
Merck KGaA
NewBay Medical Technology Co Ltd
Ningbo Tai Kang Medical Technology Co Ltd
Novartis AG
Novelty Nobility Inc
Omeros Corp
Otsuka Pharmaceutical Co Ltd
PDS Biotechnology Corp
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Protheragen Inc
Qualigen Therapeutics Inc
Repare Therapeutics Inc
Sartar Therapeutics Ltd
Shanghai Affinity Biopharmaceutical Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Soricimed Biopharma Inc
Taivex Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Tarapeutics Science Inc
Theseus Pharmaceuticals Inc
TotalClarity Inc
Virocure Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Mesenchymal Tumor reports